CBD and Autism

CBD and Autism

A paper analyzing recent peer-reviewed literature to identify the current state of evidence regarding CBD use for those affected by autism. At this time, three large-scale clinical trials are currently at varying stages of progress and publication of results. Only five small studies were identified that have specifically examined cannabis use and autism. Studies which examined effects of cannabis on shared symptoms of autism such as hyperactivity, sleep disorders, self-injury, anxiety, behavioral problems, and communication were also reviewed.

Five research studies exist which have examined the direct effects of medical cannabis in individuals with autism. The most recently published study conducted in Israel, examined the safety and efficacy of medical cannabis use amongst 188 patients . Patients were treated using cannabis oil (1.5% THC and 30% CBD), and functional activities of daily living, mood, and quality of life were assessed using structured. A third of participants reported significant improvements (Schleider et al., 2019)

With a focus on behavioral problems in children and youth with autism, researchers in Jerusalem are studying the efficacy of a cannibinoid mix, while also examining safety and tolerance. The study is a double-blind randomized placebo-controlled trial and the cannabinoid mix consists of a 20:1 ratio in a 160/ 8.0 mg per ml of CBD/THC olive oil-based solution . Results from this clinical trial are eagerly anticipated

There is an urgent need for additional controlled studies to increase understanding of risks and benefits and also to examine the impact of “entourage effects.” These additional studies would support discussions of treatment options between health care providers and autism patients and their families.

References

Bar-Lev Schleider L, Mechoulam R, Saban N, Meiri G, Novack V. Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy. Sci Rep. 2019;9:200.

Biological effects of lesser known Phytocannabinoids

Of the 100+ phytochemicals that are found in the cannabis plant, we only really have evidence on the biological and potential therapeutic effects of THCA, THCV, CBDA, CBV, CBG and CBC. Of these, only THCV (in diabetes and metabolic disorders) and CBDV (in epilepsy and autism) have been tested as single molecules in humans. From animal and cell line studies, we know that THCA, THCV, and CBDA may have a role in reducing nausea. CBG might also help stimulate appetite. As these compounds are not psychotropic, they may be preferential to THC, which patients often use for nausea and appetite stimulation in cancer and HIV. THCA, THCV, CBG and CBC all have anti-inflammatory properties in various models, with therapeutic applications against a wide range of inflammatory disorders. CBDA, CBG and CBC have potential anti-tumoral properties. THCV and CBG might also be protective in various neurological disorders. Much further research is require to translate some of these promising findings into clinical trials to prove effectiveness of these compounds either as single compounds or as combinations of phytocannabinoids, in humans.

CBD and the NFL

Chris Long uses CBD and thinks the NFL should allow it. “I just think it’s dumb I think it’s arbitrary,” He said, alluding to people’s objectionable views on cannabis use. “You’re tarnishing the brand and popularity of some guys who could be great stars in the league, but you’re making them these poster children for the devil’s lettuce when you pop them with a test. It’s pointless.”

Long is no stranger to talking about weed. In May 2019 interview on “The Dan Patrick Show,” shortly after announcing his retirement after 11 seasons in the NFL, he opened up about his cannabis use, stating, “I certainly enjoyed me fair share on a regular basis through my career.”


Terrell Davis a former Hall of Fame Running back also endorses CBD use for NFL Players and believes CBD use would have extended his career.

In an interview with TMZ Sports published on Thursday, Davis noted that he feels CBD would have lessened the toll that playing football took on his body:

Former Patriots tight end Rob Gronkowski said that CBD has helped him immensely and he wants the same opportunities for friends and teammates.

“I believe so, because any time you can help your body heal—you can take out the swelling, the inflammation and you can do it in a way that’s natural—I feel like absolutely it would have assisted in that,” Davis said.

The NFL’s policy on weed continues to lag behind the times. Players who fail an initial drug test are placed in an “intervention program.” Future failed tests thereafter can result in suspensions.

And this year, the National Football League Players’ Association partnered with the NFL to study marijuana and CBD as alternatives to other pain therapies, namely opioids.

Rob Gronkowski promoting his CBD company.

CBG – Promising Effects on Depression and Anxiety

Cannabigerol (CBG) was first discovered by scientists in 1964 as a component of hashish. CBG belongs to the non-psychoactive group of cannabinoids. Research into its medical properties is currently ongoing. Though it has not been studied as intensively as the other cannabinoids like CBD or THC, results obtained so far from studies suggest that it is enriched with loads of health benefits for the consumer.

Treatment for depression and anxiety: It has been proven that THC can have positive effects on patients suffering from depression. CBG has shown similar effects but without the accompanying psychotic effects that THC is known for. A 2016 report has suggested that CBG and other non-psychotic cannabinoids could effectively treat depression and anxiety.

CBG reduces inflammation by acting on special molecules that trigger the inflammatory processes in many disease states such as cancer, inflammatory bowel disease, and pain syndromes.

CBG is a cannabinoid with particular medical properties that may have beneficial health benefits for people suffering from a variety of diseases and disorders. It is apparent that with more research, development, and education, cannabinoids such as CBG, could offer safer, more natural disease-targeted alternatives to conventional treatments. 

References

Cannabigerol. https://chem.nlm.nih.gov/chemidplus/sid/0025654313

ChemIDplus Chemical Information Classification

https://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp

Ranja, AG.; Carrillo-Salinas, F.; Pagani, A.; Gómez-Cañas, M.; Negri, R.; Navarrete, C.; Mecha, M.; Mestre, L.; Fiebich, BL.; Cantarero, I.; Calzado, MA.; Bellido, ML.; Fernandez-Ruiz, J.; Appendino, G.; Guaza, C.; Muñoz, E. (2012). “A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis”. J Neuroimmune Pharmacol. 7 (4): 1002–16. doi:10.1007/s11481-012-9399-3PMID22971837.

Hala N. Eisohly, Carlton E. Turner, Alice M. Clark, Mahmoud A. Eisohly (1982). Synthesis and antimicrobial activities of certain cannabichromene and cannabigerol related compounds

George ANASTASSOV, Lekhram Changoer (2014). Oral care composition comprising cannabinoids


One Farm’s Experience No-Tilling CBD Hemp

No-tiller David Groff from Cedar Meadow Farm in Holtwood, Pa., talks about the farm’s experience this year no-tilling hemp and the cover-crop mix and fertility plan they followed during the growing season. He also talks about the effect weeds and vegetation had on insect pests targeting their crop.

The Pharmacology of Cannabis Cannabinoids and Terpenes by Dr. Ethan Russo

Understanding the Pharmacology of Cannabis. Dr. Ethan Russo speaks about the science of Cannabis Cannabinoids and Terpenes at the Cannabis Hemp Conference and Expo (CHCE).

Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Medical Director of PHYTECS, a biotechnology company researching and developing innovative approaches targeting the human Endocannabinoid system. Previously, from 2003-2014, he served as Senior Medical Advisor and study physician to GW Pharmaceuticals for numerous Phase I-III clinical trials of Sativex® for pain and MS, and initial studies of Epidiolex® for intractable epilepsy. He graduated from the University of Pennsylvania (Psychology) and the University of Massachusetts Medical School, before residencies in Pediatrics in Phoenix, Arizona and in Child/Adult Neurology at the University of Washington. He was a clinical neurologist in Missoula, Montana for 20 years. He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, in Medicine at the University of Washington, and as visiting professor, Chinese Academy of Sciences. He is a Past-President of the International Cannabinoid Research Society, and former Chairman of the International Association for Cannabinoid Medicines. He serves on the Scientific Advisory Board for the American Botanical Council. He has published several books, numerous book chapters, and over forty articles in neurology, pain management, cannabis, and ethnobotany. He has consulted or lectured on these topics in more than 30 US states and 30 countries.

The NEST, University of British Columbia
May 6-7th, 2017
Vancouver, Canada

CannabisHempConference.com